- $36.55m
- $29.39m
- $0.04m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 8.16 | ||
| Price to Tang. Book | 8.16 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 849.92 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -176.68% | ||
| Return on Equity | -1192.69% | ||
| Operating Margin | -25511.63% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | 0.04 | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
RenovoRx, Inc. is a clinical and a commercial biopharmaceutical company. Its lead product RenovoCath a local drug delivery device, targeting high unmet medical needs. RenovoRx’s patented Trans-Arterial Micro-Perfusion (TAMP) therapy platform is designed to ensure targeted therapeutic delivery across the arterial wall near the tumor site to bathe the target tumor. RenovoRx’s novel approach to targeted treatment offers the potential for increased safety, tolerance, and improved efficacy, and to transform the lives of cancer patients by providing innovative solutions to enable targeted delivery of diagnostic and therapeutic agents. In addition to the RenovoCath device, RenovoRx is also evaluating the novel Phase III drug-device combination oncology product candidate (intra-arterial gemcitabine, known as IAG). The combination of intra-arterial infusion of chemotherapy, gemcitabine, and the RenovoCath device is being evaluated for the treatment of locally advanced pancreatic cancer.
Directors
- Shaun Bagai CEO (44)
- Kamran Najmabadi FDR
- Ramtin Agah FDR (55)
- Paul Manners VFN (70)
- David Diamond IND (59)
- Kristen Macfarlane IND (56)
- Laurence Marton IND (77)
- Una Ryan IND (79)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- December 17th, 2012
- Public Since
- August 17th, 2021
- No. of Shareholders
- 129
- No. of Employees
- 10
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
NASDAQ Capital Market- Shares in Issue
- 36,551,752
- Address
- 2570 W. EL CAMINO REAL, STE. 320,, MOUNTAIN VIEW, 94040
- Web
- https://renovorx.com/
- Phone
- +1 4088002649
- Contact
- Valter Pinto
- Auditors
- Frank ,Rimerman Co.LLP
Upcoming Events for RNXT
Q1 2025 RenovoRx Inc Earnings Release
Q1 2025 RenovoRx Inc Earnings Call
Q1 2025 RenovoRx Inc Earnings Call
RenovoRx Inc Annual Shareholders Meeting
RenovoRx Inc Annual Shareholders Meeting
Q2 2025 RenovoRx Inc Earnings Release
Q2 2025 RenovoRx Inc Earnings Release
Similar to RNXT
Accelerate Diagnostics
NASDAQ Capital Market
Adagio Medical Holdings
NASDAQ Capital Market
Adapthealth
NASDAQ Capital Market
Aethlon Medical
NASDAQ Capital Market
Agape ATP
NASDAQ Capital Market
FAQ
What is the RenovoRx share price?
As of Today at 22:55 UTC, shares in RenovoRx are trading at $1.00. This share price information is delayed by 15 minutes.
How has the RenovoRx share price performed this year?
Shares in RenovoRx last closed at $1.00 and the price had moved by -21.26% over the past 365 days. In terms of relative price strength the RenovoRx share price has underperformed the S&P500 Index by -29% over the past year.
What are the analyst and broker recommendations for RenovoRx?
There is no consensus recommendation for this security.
Find out moreWhat is the RenovoRx dividend yield?
RenovoRx does not currently pay a dividend.
Does RenovoRx pay a dividend?
RenovoRx does not currently pay a dividend.
When does RenovoRx next pay dividends?
RenovoRx does not currently pay a dividend.
How do I buy RenovoRx shares?
To buy shares in RenovoRx you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of RenovoRx?
As of the previous close price of $1.00, shares in RenovoRx had a market capitalisation of $36.55m.
Where are RenovoRx shares listed?
Here are the trading details for RenovoRx:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: RNXT
What kind of share is RenovoRx?
Based on an overall assessment of its quality, value and momentum RenovoRx is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a RenovoRx share price forecast for 2025?
We could not find analyst target price data for this security.
Find out moreWhat is the trend in the RenovoRx share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like RenovoRx. Over the past six months, its share price has underperformed the S&P500 Index by -1.51%.
As of the last closing price of $1.00, shares in RenovoRx were trading -10.14% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the RenovoRx PE Ratio?
The RenovoRx PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $1.00.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of RenovoRx?
RenovoRx's management team is headed by:
- Shaun Bagai - CEO
- Kamran Najmabadi - FDR
- Ramtin Agah - FDR
- Paul Manners - VFN
- David Diamond - IND
- Kristen Macfarlane - IND
- Laurence Marton - IND
- Una Ryan - IND